NMN (Nicotinamide Mononucleotide): FDA Drug Preclusion Reversal & Supplement Status

What Is NMN?

Beta-nicotinamide mononucleotide (β-NMN), commonly known as NMN, is a naturally occurring nucleotide derived from ribose and nicotinamide. It serves as a direct precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular energy metabolism, DNA repair, and gene expression. NAD+ levels decline significantly with age, and NMN supplementation has emerged as one of the most studied strategies for restoring those levels.

Property	Value
Chemical Name	Beta-nicotinamide mononucleotide
CAS Number	1094-61-7
UNII	1094N0V2PA
Molecular Formula	C₁₁H₁₅N₂O₈P
Molecular Weight	334.22 g/mol

NMN belongs to the NAD+ precursor family alongside nicotinamide riboside (NR) and niacin (vitamin B3). The NMN supplement market exploded in the early 2020s, driven by anti-aging research from Harvard Medical School, Washington University in St. Louis, and Keio University in Japan — and by the advocacy of Dr. David Sinclair, whose work on sirtuins and NAD+ decline popularized NMN supplementation worldwide.

By 2022, NMN was one of the fastest-growing dietary supplement ingredients in the United States, with a market estimated at ~$280 million. Then the FDA intervened.

FDA Regulatory Status

Current status (March 2026): NMN is a lawful dietary supplement ingredient. The FDA formally reversed its drug preclusion exclusion on September 29, 2025, and reinstated NMN's New Dietary Ingredient (NDI) status on December 2, 2025. Companies must file an NDI notification at least 75 days before marketing.

This straightforward status belies one of the most contentious regulatory battles in recent supplement industry history.

Key Deadlines

Date	Event	Status
~2017	NMN first marketed as dietary supplement in U.S.	Establishes "race to market" priority
October-November 2022	FDA issues drug preclusion exclusion (NDIN 1247, 1259)	Reversed
March 13, 2023	Amazon delists all NMN supplements	Restored Oct 2025
March 7, 2023	NPA/ANH citizen petition filed (FDA-2023-P-0872)	Granted
August 28, 2024	NPA files lawsuit in DC District Court	Dismissed
September 29, 2025	FDA reverses position — NMN declared lawful	Complete
December 2, 2025	FDA reinstates NDI status	Complete
December 10, 2025	Australia TGA approves NMN (2-year exclusivity to SyncoZymes)	Active
December 29, 2025	NPA dismisses lawsuit without prejudice	Complete
Ongoing	NDI notification required for new NMN marketers	Active requirement
TBD	EU Novel Food authorization (6 applications under EFSA review)	Pending
December 10, 2027	Australia TGA exclusivity expires	Upcoming

The Drug Preclusion Battle

The DSHEA Drug Preclusion Clause

Section 201(ff)(3)(B) of the FD&C Act states that a substance cannot be marketed as a dietary supplement if it was first authorized for investigation as a new drug (IND) and substantial clinical investigations have been instituted and made public — unless the substance was marketed as a food or supplement before the IND authorization.

Metro International Biotech and MIB-626

Metro International Biotech, co-founded by Dr. David Sinclair, developed MIB-626 — a pharmaceutical-grade crystalline NMN formulation — and filed an IND application. The company launched Phase 2 clinical trials for exercise performance and Alzheimer's disease. FDA's 2022 determination concluded that Metro's IND authorization preceded NMN's marketing as a dietary supplement.

The FDA's October-November 2022 Exclusion

The FDA issued Category 4 responses to two NDI notifications:

• NDIN 1247 from SyncoZymes (October 11, 2022)
• NDIN 1259 from Inner Mongolia Kingdomway (November 4, 2022)

Both letters concluded NMN was "excluded from the definition of a dietary supplement" under the drug preclusion clause.

Amazon Delists NMN (March 2023)

Amazon banned all NMN supplements effective March 13, 2023, cutting off the primary retail channel overnight. Some brands pivoted to selling as "research compounds" or through DTC channels; others reformulated with nicotinamide riboside (NR).

The Citizen Petition and Lawsuit

On March 7, 2023, the Natural Products Association (NPA) and Alliance for Natural Health USA (ANH) filed citizen petition FDA-2023-P-0872, arguing NMN was marketed as a supplement as early as 2017 — before Metro's IND. The FDA failed to respond within the statutory timeframe.

On August 28, 2024, NPA filed suit in DC District Court. Judge Paul L. Friedman granted a stay on October 30, 2024, giving FDA time to respond.

The September 2025 Reversal

On September 29, 2025, the FDA issued a 26-page response reversing its exclusion. The agency concluded:

1. There was sufficient evidence that NMN was marketed as a supplement before the IND authorization
2. NMN was not excluded from the dietary supplement definition
3. The prior Category 4 determinations were rescinded

NPA called it a "monumental victory." The Council for Responsible Nutrition (CRN) expressed disappointment that the response was narrow — addressing only NMN rather than providing systematic clarity on the drug preclusion clause.

NDI Reinstatement and Market Restoration

• October 2025: NMN returns to Amazon
• December 2, 2025: FDA formally reinstates NDI status for SyncoZymes and Kingdomway
• December 29, 2025: NPA dismisses lawsuit without prejudice

The Broader Drug Preclusion Problem

The Confidential IND Problem

IND effective dates are confidential. Supplement companies have no way of knowing whether a pharma company has filed an IND for an ingredient they're already marketing. NMN's three-year limbo caused real economic harm.

Other Ingredients at Risk

The drug preclusion clause has been invoked or threatened against:

• CBD (cannabidiol) — excluded due to Epidiolex IND, still unresolved
• NAC (N-acetyl-L-cysteine) — initially threatened, later enforcement discretion
• Peptides and next-generation ingredients — industry warns any ingredient attracting pharmaceutical interest could face similar treatment

Congressional Activity

No enacted legislation addresses the drug preclusion clause as of March 2026. Reform proposals include requiring meaningful clinical development (not just IND filing) before preclusion attaches, categorical exemption for pre-DSHEA ingredients, and a sunset provision if drug development is abandoned for 7 years.

International Status

Japan — Most Permissive

MHLW classified NMN as a food ingredient in 2020. Japan is the most mature NMN market in Asia, with 13 functional food claim products registered between 2023-2025.

Australia — Newly Approved

TGA approved NMN on December 10, 2025, with two-year market exclusivity to SyncoZymes through December 10, 2027.

European Union — Not Yet Authorized

NMN is classified as a Novel Food. Six applications have been submitted, with EFSA safety evaluation initiated for some. No authorization has been granted as of March 2026.

China — Prohibited in Food

Despite being a major NMN manufacturer, China prohibits NMN in domestic food and supplement products. Products may be sold only through cross-border e-commerce channels.

Canada

NMN is listed in the Natural Health Products Ingredients Database, permitting sale as a Natural Health Product.

Affected Product Categories

• Anti-aging and longevity supplements — the primary market
• NAD+ precursor products — NMN competes with NR and niacin
• Sports nutrition and performance — based on exercise capacity research
• Cognitive health and nootropics — based on Alzheimer's research
• Combination formulations — frequently combined with resveratrol, quercetin

What Companies Should Do

Immediate Compliance

1. File or confirm NDI notification. Every company marketing NMN must have a valid NDIN on file, or source from a supplier whose NDIN covers downstream use.

2. Review labeling. Structure/function claims with appropriate disclaimers only. No disease claims.

3. Verify supply chain. Confirm supplier NDI coverage, cGMP compliance (21 CFR Part 111), and third-party testing.

4. Document "race to market" evidence. If you marketed NMN before 2022, preserve all records — product listings, invoices, marketing materials, website archives.

Strategic Considerations

5. Monitor pharmaceutical development. Metro International Biotech's clinical trials continue. Any new regulatory interpretation could create complications.

6. Track congressional action. Legislative reform of the drug preclusion clause would provide permanent structural protection.

7. Watch international developments. EU Novel Food process and Australia's TGA exclusivity will shape global market access through 2027-2028.

8. Diversify NAD+ precursor portfolio. The exclusion period demonstrated single-ingredient dependence risk.

Regulatory Intelligence

Policy Canary tracks FDA regulatory actions, citizen petitions, enforcement signals, and international developments across all supplement categories. Subscribe to receive alerts when new regulatory actions affect your products.